Context Therapeutics Inc.
CNTX
$0.775
$0.0020.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.22M | 7.06M | 6.88M | 7.01M | 7.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 29.92M | 32.55M | 20.03M | 22.23M | 25.07M |
| Operating Income | -29.92M | -32.55M | -20.03M | -22.23M | -25.07M |
| Income Before Tax | -26.73M | -30.15M | -18.57M | -21.32M | -23.96M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.73 | -30.15 | -18.57 | -21.32 | -23.96 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.73M | -30.15M | -18.57M | -21.32M | -23.96M |
| EBIT | -29.92M | -32.55M | -20.03M | -22.23M | -25.07M |
| EBITDA | -29.91M | -32.54M | -20.01M | -22.22M | -25.06M |
| EPS Basic | -0.53 | -0.91 | -1.06 | -1.34 | -1.50 |
| Normalized Basic EPS | -0.33 | -0.57 | -0.66 | -0.83 | -0.94 |
| EPS Diluted | -0.57 | -0.91 | -1.06 | -1.34 | -1.50 |
| Normalized Diluted EPS | -0.33 | -0.57 | -0.66 | -0.83 | -0.94 |
| Average Basic Shares Outstanding | 233.34M | 167.37M | 102.86M | 63.86M | 63.86M |
| Average Diluted Shares Outstanding | 233.34M | 167.37M | 102.86M | 63.86M | 63.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |